• Dihydroergotamine (DHE) is a semi-synthetic form of ergotamine approved in the US in 1946. (wikipedia.org)
  • D.H.E. 45 (dihydroergotamine) ® is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. (rxlist.com)
  • When ergotamine or dihydroergotamine are concurrently administered with azithromycin ergot toxicity may occur. (entirelypetspharmacy.com)
  • Erythromycin is contraindicated in patients taking terfenadine or astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (See WARNINGS and PRECAUTIONS Drug Interactions).Do not use erythromycin concomitantly with 3-hydroxy-3-methylglutaryl-coenzyme (HMG CoA) reductase inhibitors (statins) that are extensively metabolized by cytochrome P450 isoform 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (See WARNINGS and PRECAUTIONS Drug Interactions). (drugcentral.org)
  • This study randomises forty patients (1:1) to receive either eptinezumab or an infusion of intravenous lignocaine for up to 5 days. (bmj.com)
  • It will assess the effect of eptinezumab compared with intravenous lignocaine in aborting status migrainosus, with the primary outcome of time from infusion until resolution of pain. (bmj.com)
  • Prostaglandin E 1 also dilates blood vessels, and it is sometimes administered by intravenous infusion to treat peripheral vascular disease . (britannica.com)
  • Dihydroergotamine mesylate injection (also known as DHE injection), which is mostly used as headache centers as an intravenous (IV) infusion. (kaizenbraincenter.com)
  • Because dihydroergotamine (DHE) is a costly infusion, encounters at which DHE was administered were analyzed separately. (bvsalud.org)
  • h/mL, respectively, in normal volunteers receiving a 3-hour intravenous infusion of 500 mg azithromycin at a concentration of 1 mg/mL. (nih.gov)
  • The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes. (neurologylive.com)
  • Their data, which assessed the impact of the infusion rate of intravenous DHE-in either 60 minutes or 90 to 120 minutes—on inpatient treatment outcomes, suggest that prolonging the infusion time to manage cramping led to an improvement of adverse effects without interfering with efficacy. (neurologylive.com)
  • Effect of Dihydroergotamine Infusion Rate on Inpatient Headache Treatment Outcomes. (neurologylive.com)
  • Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized.Allergic reactions ranging from urticaria to anaphylaxis have occurred. (drugcentral.org)
  • ErythrocinTM Lactobionate-IV (erythromycin lactobionate for injection, USP) is lyophilized powder for intravenous infusion only. (drugcentral.org)
  • In critically ill patients, midodrine has been used as either an adjunctive oral therapy to wean vasoplegic patients off low dose intravenous vasopressor infusions, or as an oral vasopressor agent to prevent or minimise the need for intravenous infusion. (cicm.org.au)
  • Remdesivir is given through the vein (intravenous or IV infusion) over 60 minutes. (bilh.org)
  • The recommended dose for children is based on body weight and is given as an intravenous infusion over 15 minutes, starting about 30 minutes before the chemotherapy. (pharmachoice.com)
  • Intravenous injection is considered very effective for severe migraine or status migrainosus. (wikipedia.org)
  • D.H.E. 45 (dihydroergotamine mesylate) is an ergot alkaloid used to treat a migraine or cluster headache attack. (rxlist.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. (rxlist.com)
  • An example of an ergot alkaloid used in a migraine cocktail is dihydroergotamine. (healthline.com)
  • Dihydroergotamine, a derivative, can be used in treating migraine. (britannica.com)
  • BACKGROUND: Dihydroergotamine (DHE) has long been used to treat migraine, but intravenous administration is invasive, frequently associated with adverse events (AEs), and not suitable for at-home administration. (bvsalud.org)
  • STOP 301: A phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, precision olfactory delivery (POD ®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. (reliasmedia.com)
  • Strong migraine medications, such as dihydroergotamine, sumatriptan, or valproate, can be administered intravenously, subcutaneously or intramuscularly - depending on the type of medication - to treat status migrainosus. (painscale.com)
  • Dihydroergotamine (DHE) has been used in the treatment of migraine for quite a long period of time, and in recent years, the interest in attempting to optimize this oft used but somewhat unchanged therapy has increased. (neurologylive.com)
  • DHE is available as a nasal spray and in ampules for subcutaneous, intramuscular and intravenous injection. (wikipedia.org)
  • Dihydroergotamine mesylate (DHE) has been available as a nasal spray (Migranal) since 1997. (reliasmedia.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. (rxlist.com)
  • Serious cardiac events, including some that have been fatal, have occurred following use of D.H.E. 45® (dihydroergotamine mesylate) Injection, USP, but are extremely rare. (rxlist.com)
  • Azithromycin for injection contains the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics, for intravenous injection. (nih.gov)
  • Reconstitution, according to label directions, results in approximately 5 mL of azithromycin for intravenous injection with each mL containing 100 mg azithromycin (from azithromycin monohydrate). (nih.gov)
  • The dose for voriconazole intravenous (into the vein) injection depends on body weight and the type of infection. (pharmasave.com)
  • The recommended adult dose is 0.25 mg given as an injection into the vein (intravenous) over 30 seconds, and about 30 minutes before you get your anticancer medicine (chemotherapy). (pharmachoice.com)
  • Dihydroergotamine (DHE), sold under the brand names D.H.E. 45 and Migranal among others, is an ergot alkaloid used to treat migraines. (wikipedia.org)
  • 2 INP104 showed comparable bioavailability with intravenous DHE and shorter time to reach peak plasma levels and four times higher plasma levels than Migranal. (reliasmedia.com)
  • 22. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects. (shrewdconsulting.com)
  • Intravenous fluids may be needed to treat dehydration from prolonged nausea and vomiting. (painscale.com)
  • Comparison of the plasma pharmacokinetic parameters following the 1st and 5th daily doses of 500 mg intravenous azithromycin showed only an 8% increase in C max but a 61% increase in AUC 24 reflecting a threefold rise in C 24 trough levels. (nih.gov)
  • The dose can be repeated, as needed, at 1 hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24 hour period. (rxlist.com)
  • The aim of this study is to assess the efficacy and safety of eptinezumab in the treatment of status migrainosus in comparison to intravenous lidocaine. (bmj.com)
  • Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (rxlist.com)
  • For patients who fail to respond to simple analgesia, triptans and intravenous prochlorperazine or chlorpromazine, there are limited treatment options, and a paucity of high-quality evidence to guide clinical practice. (bmj.com)
  • For example, people with TMJ patients include intravenous normal its medicinal reputation. (meloathens.com)
  • Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. (rxlist.com)
  • See WARNINGS).Side effects following the use of intravenous erythromycin are rare. (drugcentral.org)
  • Clinical trials have mostly focused on midodrine as an intravenous vasopressor weaning agent. (cicm.org.au)
  • Our D.H.E. 45 (dihydroergotamine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • Eptinezumab, an intravenous monoclonal antibody specific for the calcitonin gene-related peptide ligand which achieves maximal plasma concentration immediately following administration and may improve migraines from day one. (bmj.com)
  • After showing antitumour activity in two single-arm trials 1 , 2 , a phase III trial compared oral crizotinib to intravenous chemotherapy. (tg.org.au)
  • Thus, plasma concentrations are higher following the intravenous regimen throughout the 24 hour interval. (nih.gov)
  • Dihydroergotamine (DHE), sold under the brand names D.H.E. 45 and Migranal among others, is an ergot alkaloid used to treat migraines. (wikipedia.org)
  • Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. (nih.gov)
  • Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. (medscape.com)
  • This systematic review evaluates the safety and efficacy of intravenous (IV) lidocaine for the treatment of acute pain in adult patients. (nih.gov)
  • This pain can be mitigated by pretreatment or mixing with intravenous lidocaine. (the-medical-dictionary.com)
  • A headache attack fulfilling criteria B and C In a up with evidence that when comparing intravenous ketorolac (n 13) against intranasal sumatriptan (n 16), a Acheter generic Topamax Europe reduction in the or its receptor are emerging ineffective or cause the same after administration ( 59). (keyron.com)
  • Fridinger S and Szperka C. Intravenous dihydroergotamine associated chest pain in pediatric headache patients. (chop.edu)
  • Fridinger S and Szperka C. Effectiveness of intravenous dihydroergotamine for pediatric headache: Does headache diagnosis matter? (chop.edu)
  • Fridinger S and Szperka C. The cardiovascular impact of intravenous dihydroergotamine for pediatric headache patients. (chop.edu)
  • One of the few such inpatient centers in the world, the UCSF Inpatient Headache Unit treats patients with headache disorders through intravenous infusions of medications such as dihydroergotamine, chlorpromazine and valproate. (ucsfhealth.org)
  • When the patient failed to respond to multiple medications, the UCSF Headache Center team proposed four-day inpatient therapy with intravenous infusions of chlorpromazine. (ucsfhealth.org)
  • He was admitted to the UCSF Inpatient Headache Unit at St. Mary's Medical Center for intravenous dihydroergotamine infusions. (ucsfhealth.org)
  • The medications in a headache cocktail iv may include dihydroergotamine (DHE), prochlorperazine (Compazine), and diphenhydramine (Benadryl). (easycocktailideas.com)
  • The four active controls studied were IV morphine, IV ketorolac, IV dihydroergotamine (DHE), and IV chlorpromazine (CPZ). (nih.gov)
  • Although dihydroergotamine is incompletely absorbed from the gastrointestinal tract, the low bioavailability is determined primarily by extensive first-pass hepatic metabolism. (pocketdrugguide.com)
  • INP104 utilizes our sophisticated and proprietary new device technology to deliver optimal doses of dihydroergotamine (DHE) to the vascular-rich upper nasal cavity, resulting in peak drug concentration levels that may be more effective for patients," said Stephen B. Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. (impelpharma.com)
  • [ 3 ] This issue of Pediatric Pharmacotherapy will review the pharmacology of dihydroergotamine and the steps to administering it in adolescents admitted with refractory migraines. (medscape.com)
  • Only 6% to 7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. (nih.gov)
  • Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. (nih.gov)
  • Erythromycin lactobionate for injection, USP is a soluble salt of erythromycin suitable for intravenous administration. (nih.gov)
  • Dihydroergotamine binds with high affinity to 5-HT 1D α and 5-HT 1D β receptors. (nih.gov)
  • Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. (nih.gov)
  • Study authors claimed this was the first such study to report specifically on cardiovascular AEs associated with intravenous DHE use in patients at a higher risk of ischemic events. (neurologylive.com)
  • Cite this: Intravenous Dihydroergotamine (DHE) for the Treatment of Refractory Migraines - Medscape - Jul 01, 2007. (medscape.com)
  • Dihydroergotamine (DHE) is a medication used to treat migraines and cluster headaches. (pocketdrugguide.com)
  • It may be used as a 1 mg intravenous or intramuscular dose, with this repeated after 1 hour if not effective. (mdwiki.org)
  • The pharmacokinetic profile of intravenous ganciclovir and oral valganciclovir were evaluated in 24 neonates receiving a six week treatment course for symptomatic congenital cytomegalovirus infection. (medscape.com)
  • One such treatment is intravenous (IV) therapy. (easycocktailideas.com)
  • Dihydroergotamine mesylate is 93% plasma protein bound. (nih.gov)
  • Dihydroergotamine is 90 to 95% bound to plasma proteins. (pocketdrugguide.com)
  • The major excretory route of dihydroergotamine is via the bile in the feces. (nih.gov)
  • This graph shows the total number of publications written about "Dihydroergotamine" by people in Harvard Catalyst Profiles by year, and whether "Dihydroergotamine" was a major or minor topic of these publication. (harvard.edu)
  • The intravenous form of DHE is usually administered in a healthcare setting, such as a hospital or clinic, where the patient can be monitored for potential side effects. (pocketdrugguide.com)